Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | Director | June 17, 2024 | June 18, 2024 |
| Senti Biosciences Holdings, Inc.SNTI · Entity 7935 | Director | June 25, 2025 | June 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fulcrum Therapeutics, Inc.
Report date June 17, 2024 · Filed June 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.00 · Expires 2034-06-16 | Direct | 30,000 |
Reported balance
After 2024-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 30,000 · Balance 30,000 F1: This option was granted on June 17, 2024 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 17, 2024 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service.
Senti Biosciences Holdings, Inc.
Report date June 25, 2025 · Filed June 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.05 · Expires 2035-06-24 | Direct | 21,950 |
Reported balance
After 2025-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-25 · Grant · Acquired 21,950 · Balance 21,950 F1: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Orion Biotech Opportunities Corp.
Report date May 17, 2023 · Filed May 18, 2023
Section 16 reporting ended · disclosed 2023-05-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-17 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: On April 21, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on May 17, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 21, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on May 17, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2025 Filed Jun 27, 2025 23:55 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 21,950 | $0.00 Strike: $2.05 | $0.00 |
DisclosureSEC source: 0000950170-25-091158 · ownership.xml · derivative · entry 1 Collins James J. · CIK 0001779269 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,950 Underlying: Common Stock · 21,950 shares Expires 2035-06-24 F1 · derivative.exercise_date: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2026 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:20 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 43,900 | $0.00 Strike: $3.52 | $0.00 |
DisclosureSEC source: 0001854270-25-000031 · wk-form4_1741724446.xml · derivative · entry 1 Collins James J. · CIK 0001779269 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,900 Underlying: Common Stock · 43,900 shares Expires 2035-03-06 F1 · derivative.exercise_date: 100% of the shares underlying this option vest on the first anniversary of the date of grant, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 20:16 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001854270-24-000085 · wk-form4_1720815383.xml · derivative · entry 1 Collins James J. · CIK 0001779269 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2034-07-09 F1 · derivative.exercise_date: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2025 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 17, 2024 Filed Jun 18, 2024 16:20 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074883 · ownership.xml · derivative · entry 1 Collins James J. · CIK 0001779269 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-16 F1 · derivative.exercise_date: This option was granted on June 17, 2024 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 16:16 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0000950170-23-030752 · ownership.xml · derivative · entry 1 Collins James J. · CIK 0001779269 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-26 F1 · derivative.exercise_date: This option was granted on June 27, 2023 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 23:13 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 62,500 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001854270-23-000076 · wk-form4_1687389217.xml · derivative · entry 1 Collins James J. · CIK 0001779269 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,500 Underlying: Common Stock · 62,500 shares Expires 2033-06-15 F1 · derivative.exercise_date: 100% of the shares underlying this option vest upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the 2024 Annual Meeting, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| May 17, 2023 Filed May 18, 2023 16:05 UTC | Orion Biotech Opportunities Corp. ORIA · Entity 113330 | Disposition to issuerClass B ordinary shares · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-041168 · ownership.xml · derivative · entry 1 Collins James J. · CIK 0001779269 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: On April 21, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on May 17, 2023. F1 · derivative.exercise_date: On April 21, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on May 17, 2023. F1 · derivative.expiration_date: On April 21, 2023, the Issuer announced that it will not consummate an initial business combination within the time period required. Pursuant to the Issuer's Amended and Restated Memorandum and Articles of Association (the "Articles") and in connection with the winding up of the Issuer, the Class B ordinary shares, par value $0.0001, held by the Reporting Person were surrendered for no compensation on May 17, 2023. Read SEC document |
| July 13, 2022 Filed Jul 15, 2022 22:00 UTC | Senti Biosciences Holdings, Inc. SNTI · Entity 7935 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0000899243-22-026141 · doc4.xml · derivative · entry 1 Collins James J. · CIK 0001779269 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-07-12 F1 · derivative.exercise_date: The shares underlying this option vest in 36 substantially equal monthly installments over three years from July 13, 2022, subject to the reporting person's continued service through the applicable vesting date. The vested shares subject to such option shall be exercisable upon the effectiveness of the Issuer's registration statement on Form S-8, registering the shares of the Issuer's 2022 Equity Incentive Plan with the U.S. Securities and Exchange Commission. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 17:00 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0000899243-22-024522 · doc4.xml · derivative · entry 1 Collins James J. · CIK 0001779269 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2032-06-26 F1 · derivative.exercise_date: This option was granted on June 27, 2022 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 17:11 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.85 | $0.00 |
DisclosureSEC source: 0000899243-21-023288 · doc4.xml · derivative · entry 1 Collins James J. · CIK 0001779269 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: This option was granted on June 9, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 16:15 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 9,285 | $0.00 Strike: $17.63 | $0.00 |
DisclosureSEC source: 0000899243-20-016497 · doc4.xml · derivative · entry 1 Collins James J. · CIK 0001779269 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,285 Underlying: Common Stock · 9,285 shares Expires 2030-06-10 F1 · derivative.exercise_date: This option was granted on June 11, 2020 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service. Read SEC document |
| July 18, 2019 Filed Jul 18, 2019 17:28 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | GrantStock Option (right to buy) · Derivative | 5,714 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001104659-19-040972 · a4.xml · derivative · entry 1 Collins James J. · CIK 0001779269 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,714 Underlying: Common Stock · 5,714 shares Expires 2029-07-17 F1 · derivative.exercise_date: The option was granted on July 18, 2019. The shares underlying the option are scheduled to vest on July 18, 2020 or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.